LOG IN

Members and suppliers: Join our online community

Access our full library of resources, register for events and webinars and share audits and other assessments

News

Sort By
This bulletin was published 15 hours ago
Decarbonizing the healthcare supply chain: strategic actions for health systems

Decarbonizing the healthcare supply chain: strategic actions for health systems

The WHO Alliance for Transformative Action on Climate Change has just published a new guidance: Decarbonizing the healthcare supply chain - strategic actions for health systems.

Overview
This report highlights practical actions for health systems to decarbonize their supply chain, depending on their local context and priorities. It outlines two complementary approaches: accelerating supplier decarbonization through procurement and optimizing demand and usage of supplies.

The report encourages better understanding of supply chain hotspots, partnership working and international alignment, while also discussing the key steps that will lead to the most transformative action moving forward. These approaches are illustrated by real-world ‘implementation examples’ embedded in the report. The PSCI's resources and work are mentioned in this report.

Read the report here.

The report was co-authored by NHS England, the WHO, Australian Government Department of Health, Disability and Ageing; Health Service Executive, Ireland; Ministry of Health, France; Ministry of Health, Germany; and Norwegian Hospital Procurement Trust, as part of an ATACH Task Team.

Attend the launch webinar
Join the live event at COP30 at 09.00-10.00 (BRT) Friday 21st November at the Health Pavilion. This event will include a discussion of key approaches to healthcare supply chain decarbonisation, raising awareness, inspiring action and accelerating global efforts to decarbonize healthcare. We warmly invite you to join in person or via the livestream here.

This survey was published 15 hours ago

PSCI Decarbonization Summit - Attendee Feedback!

Thank you for joining us at the PSCI Decarbonization Summit. We invite you to complete a brief 3‑question survey to share your feedback. Your insights will help shape the outcomes of the summit and guide our next steps

This resource was published on 17 November
PSCI发布2024年度报告中文版,彰显全球影响力  PSCI has released the Chinese version of its 2024 annual report

PSCI发布2024年度报告中文版,彰显全球影响力 PSCI has released the Chinese version of its 2024 annual report

Document

2025年11月17日 - 在2025年中国供应商大会期间, PSCI发布2024年度报告中文版,彰显PSCI扩大对中国供应商影响力的努力与决心。
17 Nov 2025 - PSCI released the Chinese version of its 2024 Annual Report at our 2025 China Supplier Conference in Shanghai. This move signifies PSCI's efforts in engaging more suppliers and expanding its impact in key sourcing regions for member companies.

More Info…
This resource was published on 12 November
Insights from the PSCI Audit Findings 2024: Manufacturing Excellence in the Pharma Supply Chain

Insights from the PSCI Audit Findings 2024: Manufacturing Excellence in the Pharma Supply Chain

Document

THE PSCI PRESENTS ITS ANNUAL PUBLIC AUDIT FINDINGS REPORT, PROVIDING CONTINUED INSIGHTS INTO SUPPLIER RISKS, TRENDS, AND AREAS FOR IMPROVEMENT ACROSS THE PHARMACEUTICAL AND HEALTHCARE SUPPLY CHAIN.

Pharmaceutical and healthcare companies run thousands of audits of their suppliers’ sites annually. Audits typically require between two to four days of focused, on-site effort from both the auditor and the supplier. PSCI members work together to share these audits, in support of greater transparency and valuable efficiencies that benefit both members and suppliers.

This report shares our analysis of findings from PSCI audits available on our platform. Each year, we review these in line with the PSCI Principles to identify trends, highlight improvements, and share recommendations. PSCI work with member companies, suppliers, and regional partners to turn analysis into practical guidance, training, and peer learning that suppliers can implement quickly. Overall, this analysis provides deep insight into supplier practices within the pharmaceutical and healthcare industry and suggests where collaborative efforts will have the greatest impact, guiding us on developing targeted resources and trainings.

This year’s report analyzes 2,046 findings from 228 supplier audits uploaded to the PSCI platform in 2024. These findings are categorised into 428 Governance & Management Systems findings, 26 Ethics findings, 273 Human Rights findings, 1,098 Health & Safety findings, and 221 Environment findings, offering a comprehensive overview of supplier practices and opportunities for improvement. The report includes a summary of findings across key topics, as well as a regional analysis looking at patterns across China, India, US, Western Europe, and other regions represented in this year’s uploads, presenting recommended actions for suppliers.

This bulletin was published on 12 November
Insights from the PSCI Audit Findings 2024: Manufacturing Excellence in the Pharma Supply Chain

Insights from the PSCI Audit Findings 2024: Manufacturing Excellence in the Pharma Supply Chain

THE PSCI PRESENTS ITS ANNUAL PUBLIC AUDIT FINDINGS REPORT, PROVIDING CONTINUED INSIGHTS INTO SUPPLIER RISKS, TRENDS, AND AREAS FOR IMPROVEMENT ACROSS THE PHARMACEUTICAL AND HEALTHCARE SUPPLY CHAIN.

Pharmaceutical and healthcare companies run thousands of audits of their suppliers’ sites annually. Audits typically require between two to four days of focused, on-site effort from both the auditor and the supplier. PSCI members work together to share these audits, in support of greater transparency and valuable efficiencies that benefit both members and suppliers.

This report shares our analysis of findings from PSCI audits available on our platform. Each year, we review these in line with the PSCI Principles to identify trends, highlight improvements, and share recommendations. PSCI work with member companies, suppliers, and regional partners to turn analysis into practical guidance, training, and peer learning that suppliers can implement quickly. Overall, this analysis provides deep insight into supplier practices within the pharmaceutical and healthcare industry and suggests where collaborative efforts will have the greatest impact, guiding us on developing targeted resources and trainings.

This year’s report analyzes 2,046 findings from 228 supplier audits uploaded to the PSCI platform in 2024. These findings are categorised into 428 Governance & Management Systems findings, 26 Ethics findings, 273 Human Rights findings, 1,098 Health & Safety findings, and 221 Environment findings, offering a comprehensive overview of supplier practices and opportunities for improvement. The report includes a summary of findings across key topics, as well as a regional analysis looking at patterns across China, India, US, Western Europe, and other regions represented in this year’s uploads, presenting recommended actions for suppliers.

What’s new this year?

  • A new five-year trend analysis that shows how volumes, topics and severity have changed over time. This analysis enhances our ability to monitor momentum over time and to adapt our resources to emerging risks — supporting safer work, protected rights, and reduced environmental impact throughout the value chain.

The report identifies several key findings, including:

  1. In 2024, the PSCI community uploaded more audits than ever to the PSCI platform; over 200, demonstrating great progress by PSCI’s members.
  2. Health & Safety remains the largest source of findings by volume, reflecting consistent auditor focus on this business-critical and potentially life-threatening topic.
  3. Governance and Management Systems increased in relative prominence since 2023, overtaking Environment as a proportion of total findings, reflecting greater auditor focus on risk management, supplier due diligence against international standards, and incident investigation expectations.
  4. Human Rights findings show sharper attention to contract worker treatment and alignment with international frameworks.

The report reinforces the PSCI’s role as a catalyst for continuous improvement, equipping suppliers with tools and guidance to enhance practices and adapt to evolving demands.

For more details, access the full report here.

This bulletin was published on 11 November

PSCI Audit Guidance 2025 Update - Now Available!

The SAQ/Audit & Audit Guidance sub-team have been working to update the Audit Guidance document, version 8, which is now available to download.

The main changes to the document are summarised below:

  • Updated to align with the updated PSCI Principles and Strategy
  • Inclusion of the digital Data Sharing via the PSCI Audit Platform
  • Updated audit uploading requirements for full members
  • Introduced online SAQ and removed reference of word version template
  • Referenced the Audit Checklist as a separate resource in Chapter 10
  • Added section on Managing Audit Related Issues in the appendix

If you have any questions regarding this update, please contact Miriam Davies.

  • Audit Program
This event was published on 11 November
Registration Open
Technical Workshop for Indian-based Suppliers: IH and Hazardous Area Classification

Technical Workshop for Indian-based Suppliers: IH and Hazardous Area Classification

Meeting | 10–11 Dec 2025

Join us for the final in-person technical workshop in our India supplier series - a comprehensive two-day learning event designed to strengthen supplier capabilities in workplace safety and risk management.

Day 1: Industrial Hygiene – 10 December 2025

This session focuses on Industrial Hygiene, offering participants a practical, hands-on understanding of workplace health and safety practices. Attendees will learn how to identify, evaluate, and control occupational hazards and understand how these practices contribute to compliance and overall safety performance.

Highlights:

  • Practical examples and case studies
  • Interactive Q&A and discussion

Limited to 30 in-person participants for focused engagement

Day 2: Hazardous Area Classification & LHR – 11 December 2025

Day two covers Hazardous Area Classification and Labor Human Rights (LHR). The session provides essential knowledge for maintaining safe operations in high-risk environments, including risk assessment, regulatory requirements, and practical mitigation strategies.

Highlights:

  • Hands-on learning through interactive sessions
  • Virtual access available for the LHR session
  • Limited to 30 in-person participants to ensure active participation

Mode of Training:
Classroom (in-person) for both days, with a virtual option available for the LHR session only.

Please register only if you plan to attend in person. For virtual participation in the LHR session, please email us here

Type
Meeting
Date
10–11 Dec 2025
Language
English

If you have a PSCI account, please log in first so your information will be filled automatically.

All fields are required except where specified. Please enter all information in English.

Full Members

  • Abbott
  • Acino International AG
  • AstraZeneca
  • Aurobindo
  • BASF Pharma
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Centrient Pharmaceuticals
  • Coloplast
  • Elanco Animal Health
  • Grunenthal GmbH
  • GSK
  • Haleon
  • Johnson & Johnson
  • Kenvue
  • Lilly
  • Mallinckrodt
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Orion
  • Pfizer
  • Piramal
  • Roche
  • Sandoz
  • Sanofi
  • Sartorius
  • Takeda
  • Teva
  • UCB
  • Viatris
  • West Pharmaceutical Services Inc.
  • Zoetis

Associate Members

  • AbbVie
  • Alkem Laboratories
  • Almirall
  • Amgen
  • Amgros
  • Aragen Life Sciences Limited
  • Aspen Pharmacare
  • Bavarian Nordic
  • Baxter
  • Becton Dickinson
  • Biogen
  • Charles River Laboratories
  • Chiesi
  • Chugai Pharmaceutical
  • Cipla
  • CSL Limited
  • Eisai Co., Limited
  • Esteve
  • Evolan Pharma AB
  • Fabbrica Italiana Sintetici S.p.a.
  • Fagron
  • Fosun Pharma
  • Fresenius Kabi
  • Gilead
  • Hameln Pharma
  • Immedica Pharma
  • IOI Oleo
  • Karo Healthcare
  • Kyowa Kirin
  • LEO Pharma
  • Mallax Pharmaceutical
  • Merck KGaA
  • Moderna
  • Nordic Group B.V.
  • Ono Pharmaceuticals
  • Organon
  • Orifarm
  • Perrigo Company
  • Sai Life Sciences
  • Shionogi
  • SK Biopharmaceuticals
  • Sobi
  • STADA
  • Sterling Pharma Solutions
  • ten23 health
  • Tiefenbacher Group
  • Vertex
  • Vetoquinol
  • Xellia Pharmaceuticals
  • Zentiva

We will not pass on these details to third parties and will use them only to contact you about this event, or other PSCI events we think you may be interested in.

Please contact us if you find you can no longer attend.

I understand that these details will be used by the PSCI to identify me and to send me communications relating to this, and future, PSCI events.

Leave this field blank if you are a human.
Registration Closes: 10 Dec 2025
If you have a user account, please log in before registering.
This event was published on 11 November
CPHI & PMEC India 2025

CPHI & PMEC India 2025

External | 25–27 Nov 2025

CPHI & PMEC India unites South Asian pharma excellence. Join the event to discover innovation and connect face-to-face. Connect with thousands of industry leaders and expand your network with endless opportunities to learn, innovate, and collaborate online and in-person.

CPHI facilitates opportunities for you to grow your business and develop meaningful connections at the heart of pharma in India. Experience the latest industry trends, groundbreaking innovations, and informative sessions while networking in our match and meet lounge.

The PSCI will be speaking at CPHI & PMEC India and is delighted to be supporting the event as an Association Partner for the second year.

Please consult the agenda for further details.

Type
External
Date
25–27 Nov 2025
Language
English
This resource was published on 7 November

PSCI engages with Members & Supplier Partners at CPHI Frankfurt 2025

Video

The PSCI was delighted to exhibit at CPHI Frankfurt 2025 as an Official Sustainability Partner of the conference. We engaged with Members, Supplier Partners, and other Partners all working towards building responsible supply chains.

Check out our highlights video and see you next year at CPHI Milan!

This event was published on 29 October
Registration Open
Webinar: AMRの脅威と製薬企業の責任 The Threat of AMR and Pharmaceutical Responsibility

Webinar: AMRの脅威と製薬企業の責任 The Threat of AMR and Pharmaceutical Responsibility

Webinar | 22 Dec 2025 15:00–16:00 Tokyo

この講演の言語は日本語です
This presentation will be delivered in Japanese

テーマ
AMRの脅威と製薬企業の責任:製薬業界をあげた活動とSHIONOGIグループの取り組み

PSCIアカウントに登録/ログイン後、申し込みができます。申し込みは12月17日午後5時までとなります。参加ガイドメールは12月18日に送信されます。

講演者
大橋 興三,コーポレートガバナンス部 総務EHS担当者

SHIONOGIグループにおけるEHS(環境・健康・安全)統括組織での3年間の経験を有し、AMR(薬剤耐性)対策における責任ある製造の推進を担当。AMR Industry AllianceのManufacturing Working Groupメンバーとして、国際的な枠組みにおける製造環境改善にも取り組んでいる。以前は18年間にわたり臨床開発部門にて新薬の開発業務に従事し、抗菌薬の開発にも携わる。

概略
薬剤耐性菌(AMR:Antimicrobial Resistance)は、世界の医療に深刻な影響を及ぼす重要な課題です。本Webinarでは、AMRの基本的な知識をわかりやすく解説し、製薬業界がどのように対応すべきかをご紹介します。
具体的には、AMR Industry Allianceによる抗菌薬製造基準(Antibiotic Manufacturing Standard)や、新たな認証制度を取り上げ、業界全体で進められている取り組みを理解します。
さらに、SHIONOGIグループが推進する具体的な施策についてもご紹介し、持続可能な医療の実現に向けた道筋を考えます。
AMR問題の本質と解決へのアプローチを学ぶ貴重な機会です。ぜひご参加ください。

Topic
The Threat of AMR and Pharmaceutical Responsibility: Industry-Wide Initiatives in the Pharmaceutical Sector and SHIONOGI Group’s Commitment

Presenter
Kozo Ohashi, EHS Management Group Member, Corporate Governance Department, Shionogi

Kozo Ohashi has three years of experience in the Environmental, Health, and Safety (EHS) management division of the SHIONOGI Group, where he led initiatives for responsible manufacturing in the context of antimicrobial resistance (AMR). He is also a member of the Manufacturing Working Group of the AMR Industry Alliance, contributing to global efforts to improve manufacturing practices in the fight against AMR. Prior to this role, he spent 18 years in clinical development, contributing to the research and development of new drugs, including antibiotics.

Introduction
Antimicrobial Resistance (AMR) is a critical global challenge that poses serious threats to healthcare systems worldwide. This webinar will provide a clear overview of the fundamentals of AMR and outline how the pharmaceutical industry should respond to this pressing issue.
It will introduce the Antibiotic Manufacturing Standard developed by the AMR Industry Alliance and highlight emerging certification schemes designed to ensure responsible practices across the industry. In addition, key initiatives led by the SHIONOGI Group will be presented, illustrating the path toward sustainable healthcare.
This session offers a valuable opportunity to deepen your understanding of AMR and explore practical approaches to addressing this global concern. We look forward to your participation.

Type
Webinar
Date
22 Dec 2025 15:00–16:00 Tokyo
Language
Japanese
Add To Calendar

If you have a PSCI account, please log in first so your information will be filled automatically.

All fields are required except where specified. Please enter all information in English.

Full Members

  • Abbott
  • Acino International AG
  • AstraZeneca
  • Aurobindo
  • BASF Pharma
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Centrient Pharmaceuticals
  • Coloplast
  • Elanco Animal Health
  • Grunenthal GmbH
  • GSK
  • Haleon
  • Johnson & Johnson
  • Kenvue
  • Lilly
  • Mallinckrodt
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Orion
  • Pfizer
  • Piramal
  • Roche
  • Sandoz
  • Sanofi
  • Sartorius
  • Takeda
  • Teva
  • UCB
  • Viatris
  • West Pharmaceutical Services Inc.
  • Zoetis

Associate Members

  • AbbVie
  • Alkem Laboratories
  • Almirall
  • Amgen
  • Amgros
  • Aragen Life Sciences Limited
  • Aspen Pharmacare
  • Bavarian Nordic
  • Baxter
  • Becton Dickinson
  • Biogen
  • Charles River Laboratories
  • Chiesi
  • Chugai Pharmaceutical
  • Cipla
  • CSL Limited
  • Eisai Co., Limited
  • Esteve
  • Evolan Pharma AB
  • Fabbrica Italiana Sintetici S.p.a.
  • Fagron
  • Fosun Pharma
  • Fresenius Kabi
  • Gilead
  • Hameln Pharma
  • Immedica Pharma
  • IOI Oleo
  • Karo Healthcare
  • Kyowa Kirin
  • LEO Pharma
  • Mallax Pharmaceutical
  • Merck KGaA
  • Moderna
  • Nordic Group B.V.
  • Ono Pharmaceuticals
  • Organon
  • Orifarm
  • Perrigo Company
  • Sai Life Sciences
  • Shionogi
  • SK Biopharmaceuticals
  • Sobi
  • STADA
  • Sterling Pharma Solutions
  • ten23 health
  • Tiefenbacher Group
  • Vertex
  • Vetoquinol
  • Xellia Pharmaceuticals
  • Zentiva

We will not pass on these details to third parties and will use them only to contact you about this event, or other PSCI events we think you may be interested in.

Please contact us if you find you can no longer attend.

I understand that these details will be used by the PSCI to identify me and to send me communications relating to this, and future, PSCI events.

Leave this field blank if you are a human.
Registration Closes: 17 Dec 2025
If you have a user account, please log in before registering.